AET BioTech and BioXpress Therapeutics have signed a research deal for the development of a biosimilar version of the TNF inhibitor MAb Adalimumab. Under the agreement, both the companies will be responsible for the development, ...
Tags: AET BioTech, BioXpress Therapeutics, TNF Inhibitor, research deal